| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| J9271 |
Injection, pembrolizumab, 1 mg |
1,856 |
1,231 |
$27.26M |
| 77386 |
|
9,790 |
962 |
$15.54M |
| J9299 |
Injection, nivolumab, 1 mg |
731 |
388 |
$9.07M |
| J2506 |
Injection, pegfilgrastim, excludes biosimilar, 0.5 mg |
1,194 |
777 |
$5.58M |
| 96413 |
Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance |
17,397 |
9,049 |
$4.53M |
| J9358 |
Injection, fam-trastuzumab deruxtecan-nxki, 1 mg |
741 |
264 |
$4.00M |
| J9306 |
Injection, pertuzumab, 1 mg |
448 |
284 |
$3.74M |
| J9144 |
Injection, daratumumab, 10 mg and hyaluronidase-fihj |
483 |
254 |
$3.65M |
| 77301 |
|
748 |
645 |
$3.16M |
| 78815 |
Positron emission tomography (PET) for limited area imaging |
1,964 |
1,718 |
$2.82M |
| J9355 |
Injection, trastuzumab, excludes biosimilar, 10 mg |
841 |
340 |
$2.41M |
| 71260 |
Computed tomography, thorax, diagnostic; with contrast material |
4,962 |
4,121 |
$2.04M |
| 74177 |
Computed tomography, abdomen and pelvis; with contrast material |
4,079 |
3,313 |
$1.96M |
| 80053 |
Comprehensive metabolic panel |
33,569 |
22,008 |
$1.92M |
| 77334 |
|
1,486 |
1,138 |
$1.83M |
| 99211 |
Office or other outpatient visit for the evaluation and management of an established patient, minimal severity |
37,133 |
28,947 |
$1.78M |
| 85025 |
Blood count; complete (CBC), automated, and automated differential WBC count |
60,925 |
40,223 |
$1.75M |
| 77300 |
|
1,221 |
1,017 |
$1.74M |
| 70553 |
Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences |
2,816 |
2,497 |
$1.66M |
| G0378 |
Hospital observation service, per hour |
1,850 |
706 |
$1.57M |
| 99212 |
Office or other outpatient visit for the evaluation and management of an established patient, straightforward |
26,520 |
21,999 |
$1.40M |
| 77336 |
|
3,097 |
1,459 |
$1.38M |
| J9202 |
Goserelin acetate implant, per 3.6 mg |
1,185 |
894 |
$1.25M |
| 77412 |
|
2,101 |
339 |
$1.21M |
| 96417 |
|
4,637 |
2,426 |
$1.18M |
| 96415 |
|
3,842 |
1,933 |
$1.05M |
| 76642 |
|
3,358 |
2,895 |
$1.03M |
| 77373 |
|
556 |
169 |
$924K |
| J0185 |
Injection, aprepitant, 1 mg |
1,794 |
1,058 |
$920K |
| J9035 |
Injection, bevacizumab, 10 mg |
511 |
133 |
$799K |
| J2997 |
Injection, alteplase recombinant, 1 mg |
702 |
373 |
$799K |
| 77338 |
|
714 |
613 |
$798K |
| J1454 |
Injection, fosnetupitant 235 mg and palonosetron 0.25 mg |
927 |
525 |
$797K |
| 77295 |
|
335 |
286 |
$689K |
| 80051 |
|
15,692 |
10,601 |
$661K |
| 96416 |
|
1,616 |
753 |
$626K |
| 36591 |
|
8,999 |
5,192 |
$610K |
| J9217 |
Leuprolide acetate (for depot suspension), 7.5 mg |
864 |
650 |
$600K |
| 36430 |
|
2,104 |
977 |
$564K |
| J0897 |
Injection, denosumab, 1 mg |
231 |
180 |
$546K |
| A9552 |
Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries |
1,826 |
1,601 |
$538K |
| P9037 |
Platelets, pheresis, leukocytes reduced, irradiated, each unit |
672 |
228 |
$524K |
| J9173 |
Injection, durvalumab, 10 mg |
47 |
37 |
$489K |
| 88185 |
|
10,654 |
832 |
$482K |
| 38222 |
|
432 |
317 |
$475K |
| J9022 |
Injection, atezolizumab, 10 mg |
39 |
30 |
$462K |
| 99213 |
Office or other outpatient visit for the evaluation and management of an established patient, low complexity |
6,934 |
5,285 |
$430K |
| 77385 |
|
257 |
24 |
$424K |
| 96402 |
|
3,086 |
2,275 |
$416K |
| 19083 |
|
262 |
215 |
$414K |
| 76536 |
|
1,503 |
1,356 |
$407K |
| 96365 |
Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour |
2,648 |
1,748 |
$401K |
| 77290 |
|
528 |
357 |
$400K |
| 36415 |
Collection of venous blood by venipuncture |
28,551 |
22,196 |
$400K |
| P9016 |
Red blood cells, leukocytes reduced, each unit |
623 |
433 |
$376K |
| 74183 |
|
578 |
470 |
$374K |
| 96375 |
Therapeutic injection; each additional sequential IV push |
10,118 |
5,041 |
$340K |
| 78306 |
|
596 |
485 |
$337K |
| 77066 |
Tomosynthesis, mammo |
1,901 |
1,655 |
$333K |
| 70491 |
|
987 |
833 |
$325K |
| J3490 |
Unclassified drugs |
5,877 |
2,725 |
$317K |
| 77049 |
|
360 |
327 |
$303K |
| 88307 |
|
2,343 |
964 |
$285K |
| 31575 |
|
1,404 |
1,228 |
$273K |
| J0791 |
Injection, crizanlizumab-tmca, 5 mg |
26 |
24 |
$255K |
| 80076 |
|
7,356 |
4,700 |
$254K |
| 88305 |
Level IV - Surgical pathology, gross and microscopic examination |
6,275 |
2,719 |
$254K |
| 96374 |
Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance |
3,641 |
1,935 |
$252K |
| 88341 |
|
6,326 |
1,088 |
$244K |
| 71250 |
|
1,108 |
897 |
$242K |
| 00320 |
|
358 |
279 |
$239K |
| 72197 |
|
468 |
400 |
$234K |
| Q9968 |
Injection, non-radioactive, non-contrast, visualization adjunct (e.g., methylene blue, isosulfan blue), 1 mg |
101 |
50 |
$231K |
| 82565 |
|
21,001 |
14,632 |
$231K |
| 88342 |
|
2,793 |
1,511 |
$225K |
| 31579 |
|
579 |
497 |
$211K |
| 86923 |
|
2,313 |
650 |
$208K |
| 84520 |
|
15,912 |
10,782 |
$206K |
| 36593 |
|
504 |
266 |
$202K |
| P9040 |
Red blood cells, leukocytes reduced, irradiated, each unit |
837 |
351 |
$199K |
| 83615 |
|
14,209 |
9,131 |
$193K |
| J9070 |
Cyclophosphamide, 100 mg |
1,116 |
251 |
$190K |
| 86900 |
|
4,333 |
2,427 |
$189K |
| 97140 |
Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) |
2,367 |
1,192 |
$188K |
| 36592 |
|
3,061 |
1,806 |
$186K |
| 76830 |
Ultrasound, transvaginal |
827 |
719 |
$183K |
| 74178 |
|
346 |
304 |
$178K |
| 77067 |
Screening mammography, bilateral, including computer-aided detection |
4,051 |
3,672 |
$173K |
| 96411 |
|
1,164 |
676 |
$170K |
| 83735 |
|
9,848 |
4,766 |
$167K |
| 82784 |
|
9,196 |
2,794 |
$165K |
| 96409 |
|
1,033 |
381 |
$159K |
| 88184 |
|
1,096 |
835 |
$157K |
| J1170 |
Injection, hydromorphone, up to 4 mg |
3,568 |
1,448 |
$150K |
| 96401 |
|
1,143 |
510 |
$150K |
| 52000 |
|
252 |
206 |
$150K |
| 81450 |
|
271 |
194 |
$146K |
| 84443 |
Thyroid stimulating hormone (TSH) |
9,349 |
7,355 |
$139K |
| 77065 |
Tomosynthesis, mammo |
1,051 |
928 |
$138K |
| 84439 |
|
7,712 |
6,083 |
$134K |
| 86850 |
|
4,207 |
2,385 |
$130K |
| Q9967 |
Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml |
7,849 |
6,303 |
$124K |
| 76705 |
Ultrasound, abdominal, real time with image documentation; limited |
766 |
645 |
$123K |
| G0279 |
Diagnostic digital breast tomosynthesis, unilateral or bilateral (list separately in addition to 77065 or 77066) |
2,812 |
2,460 |
$121K |
| 36561 |
|
86 |
76 |
$121K |
| 85610 |
|
9,246 |
5,459 |
$112K |
| 0202U |
Oncology (prostate), multianalyte, gene expression profiling |
199 |
145 |
$110K |
| J9395 |
Injection, fulvestrant, 25 mg |
400 |
247 |
$110K |
| G0480 |
Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed |
959 |
797 |
$108K |
| 96372 |
Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular |
3,266 |
1,792 |
$108K |
| 86905 |
|
851 |
65 |
$107K |
| 72158 |
|
184 |
157 |
$105K |
| 99202 |
Office or other outpatient visit for the evaluation and management of a new patient, straightforward |
1,440 |
1,289 |
$105K |
| 76856 |
Ultrasound, pelvic (nonobstetric), real time with image documentation; complete |
869 |
757 |
$104K |
| 76641 |
|
181 |
152 |
$102K |
| 88237 |
|
963 |
384 |
$101K |
| 97110 |
Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion |
1,817 |
908 |
$101K |
| J1750 |
Injection, iron dextran, 50 mg |
264 |
79 |
$100K |
| J9190 |
Injection, fluorouracil, 500 mg |
1,628 |
681 |
$100K |
| 86334 |
|
2,679 |
2,178 |
$98K |
| 82378 |
|
1,862 |
1,387 |
$98K |
| 76942 |
|
568 |
447 |
$95K |
| G0463 |
Hospital outpatient clinic visit for assessment and management of a patient |
13,586 |
8,224 |
$95K |
| 87799 |
|
1,978 |
694 |
$91K |
| 88360 |
|
1,026 |
328 |
$89K |
| 80307 |
Drug test(s), presumptive, any number of drug classes; immunoassay |
3,124 |
2,012 |
$85K |
| 82728 |
|
4,835 |
4,058 |
$85K |
| 96361 |
Intravenous infusion, hydration; each additional hour |
1,867 |
779 |
$84K |
| J9267 |
Injection, paclitaxel, 1 mg |
2,085 |
875 |
$84K |
| 77063 |
Screening digital breast tomosynthesis, bilateral |
3,827 |
3,452 |
$81K |
| J1459 |
Injection, immune globulin (privigen), intravenous, non-lyophilized (e.g., liquid), 500 mg |
85 |
36 |
$81K |
| 97535 |
Self-care/home management training, each 15 minutes |
1,732 |
1,232 |
$80K |
| J9075 |
Injection, cyclophosphamide, not otherwise specified, 5 mg |
252 |
70 |
$80K |
| 74176 |
Computed tomography, abdomen and pelvis; without contrast material |
266 |
225 |
$78K |
| 00400 |
|
125 |
100 |
$76K |
| 71046 |
Radiologic examination, chest; 2 views |
1,047 |
876 |
$76K |
| 84153 |
|
2,077 |
1,679 |
$76K |
| 87497 |
|
1,154 |
530 |
$75K |
| 96360 |
Intravenous infusion, hydration; initial, 31 minutes to 1 hour |
944 |
566 |
$74K |
| 72157 |
|
128 |
112 |
$74K |
| 81206 |
|
313 |
259 |
$74K |
| 82310 |
|
5,280 |
3,944 |
$73K |
| 84165 |
|
2,902 |
2,363 |
$72K |
| 80377 |
|
356 |
271 |
$71K |
| J2469 |
Injection, palonosetron hcl, 25 mcg |
5,092 |
2,641 |
$69K |
| 85027 |
|
8,432 |
4,570 |
$68K |
| 97162 |
|
826 |
712 |
$64K |
| 96377 |
|
1,224 |
787 |
$64K |
| J9045 |
Injection, carboplatin, 50 mg |
1,974 |
1,030 |
$63K |
| A9800 |
Gallium ga-68 gozetotide, diagnostic, (locametz), 1 millicurie |
33 |
25 |
$60K |
| 88313 |
|
1,498 |
565 |
$60K |
| 96367 |
|
2,105 |
1,230 |
$59K |
| 84100 |
|
5,216 |
2,663 |
$59K |
| 76770 |
|
393 |
338 |
$58K |
| 86901 |
|
4,334 |
2,427 |
$56K |
| 72156 |
|
93 |
80 |
$55K |
| 84466 |
|
2,962 |
2,528 |
$53K |
| 92612 |
|
468 |
422 |
$53K |
| A4648 |
Tissue marker, implantable, any type, each |
705 |
573 |
$53K |
| J9171 |
Injection, docetaxel, 1 mg |
518 |
289 |
$50K |
| 88264 |
|
419 |
313 |
$50K |
| 88275 |
|
1,528 |
242 |
$50K |
| 96376 |
|
2,224 |
994 |
$48K |
| J9201 |
Injection, gemcitabine hydrochloride, not otherwise specified, 200 mg |
1,466 |
406 |
$47K |
| J9206 |
Injection, irinotecan, 20 mg |
867 |
254 |
$47K |
| A9587 |
Gallium ga-68, dotatate, diagnostic, 0.1 millicurie |
15 |
13 |
$46K |
| 84432 |
|
803 |
678 |
$45K |
| 86920 |
|
580 |
121 |
$43K |
| 88271 |
|
1,753 |
255 |
$42K |
| J2704 |
Injection, propofol, 10 mg |
3,304 |
1,721 |
$42K |
| 84146 |
|
996 |
869 |
$42K |
| 81025 |
|
2,119 |
1,369 |
$41K |
| 85045 |
|
5,001 |
3,222 |
$41K |
| 84155 |
|
2,919 |
2,352 |
$41K |
| J2270 |
Injection, morphine sulfate, up to 10 mg |
1,679 |
270 |
$41K |
| 99214 |
Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity |
514 |
370 |
$40K |
| 82248 |
|
5,484 |
3,347 |
$40K |
| 78816 |
|
26 |
24 |
$39K |
| 76882 |
|
266 |
226 |
$39K |
| 97161 |
|
564 |
497 |
$39K |
| 96366 |
Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour |
1,205 |
694 |
$38K |
| 77280 |
|
88 |
77 |
$38K |
| J0330 |
Injection, succinylcholine chloride, up to 20 mg |
475 |
353 |
$37K |
| 71045 |
Radiologic examination, chest; single view |
728 |
507 |
$37K |
| J0612 |
Injection, calcium gluconate, not otherwise specified, 10 mg |
352 |
127 |
$36K |
| 82306 |
Vitamin D; 25 hydroxy, includes fraction(s), if performed |
1,780 |
1,519 |
$35K |
| J0689 |
Injection, cefazolin sodium (baxter), not therapeutically equivalent to j0690, 500 mg |
1,189 |
764 |
$35K |
| 86301 |
|
807 |
612 |
$35K |
| C1769 |
Guide wire |
487 |
361 |
$35K |
| 80048 |
Basic metabolic panel (calcium, ionized) |
1,212 |
710 |
$34K |
| 83520 |
|
2,521 |
1,123 |
$34K |
| 71271 |
|
232 |
201 |
$34K |
| J3489 |
Injection, zoledronic acid, 1 mg |
552 |
415 |
$34K |
| 82533 |
|
949 |
683 |
$33K |
| J1100 |
Injection, dexamethasone sodium phosphate, 1 mg |
6,131 |
3,415 |
$33K |
| J9263 |
Injection, oxaliplatin, 0.5 mg |
1,142 |
389 |
$33K |
| 85730 |
|
2,391 |
1,481 |
$32K |
| J3010 |
Injection, fentanyl citrate, 0.1 mg |
3,912 |
2,735 |
$32K |
| J9060 |
Injection, cisplatin, powder or solution, 10 mg |
742 |
295 |
$32K |
| 70543 |
|
63 |
52 |
$32K |
| C1726 |
Catheter, balloon dilatation, non-vascular |
118 |
98 |
$32K |
| 86304 |
|
439 |
345 |
$31K |
| 77387 |
|
212 |
40 |
$30K |
| 92597 |
|
414 |
328 |
$29K |
| 84550 |
|
3,531 |
2,044 |
$29K |
| 77080 |
|
333 |
280 |
$28K |
| J2250 |
Injection, midazolam hydrochloride, per 1 mg |
3,205 |
2,371 |
$28K |
| 77011 |
|
82 |
73 |
$28K |
| C1830 |
Powered bone marrow biopsy needle |
241 |
182 |
$27K |
| J3475 |
Injection, magnesium sulfate, per 500 mg |
1,765 |
760 |
$27K |
| 84403 |
|
878 |
714 |
$27K |
| 82947 |
|
4,431 |
2,705 |
$27K |
| 85007 |
|
5,689 |
2,991 |
$27K |
| 82040 |
|
3,271 |
2,638 |
$26K |
| J9000 |
Injection, doxorubicin hydrochloride, 10 mg |
593 |
316 |
$26K |
| G0296 |
Counseling visit to discuss need for lung cancer screening using low dose ct scan (ldct) (service is for eligibility determination and shared decision making) |
369 |
343 |
$24K |
| J1720 |
Injection, hydrocortisone sodium succinate, up to 100 mg |
494 |
339 |
$24K |
| 84703 |
|
2,000 |
1,365 |
$24K |
| 31237 |
|
18 |
13 |
$23K |
| 83540 |
|
2,971 |
2,530 |
$23K |
| 76377 |
|
215 |
195 |
$23K |
| 82670 |
|
421 |
326 |
$22K |
| 81001 |
|
2,987 |
2,114 |
$22K |
| C1788 |
Port, indwelling (implantable) |
86 |
76 |
$22K |
| 83001 |
|
571 |
450 |
$21K |
| 93005 |
Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report |
917 |
687 |
$21K |
| 80197 |
|
907 |
316 |
$19K |
| 76937 |
|
298 |
238 |
$19K |
| 70450 |
Computed tomography, head or brain; without contrast material |
86 |
66 |
$19K |
| 84075 |
|
2,986 |
2,406 |
$19K |
| J9305 |
Injection, pemetrexed, not otherwise specified, 10 mg |
320 |
75 |
$18K |
| 84450 |
|
3,050 |
2,434 |
$18K |
| 84460 |
|
2,949 |
2,373 |
$18K |
| 50200 |
|
27 |
13 |
$18K |
| 82247 |
|
3,038 |
2,418 |
$18K |
| 99215 |
Prolong outpt/office vis |
181 |
129 |
$18K |
| A9573 |
Injection, gadopiclenol, 1 ml |
1,252 |
1,123 |
$17K |
| 88112 |
|
401 |
326 |
$17K |
| J2001 |
Injection, lidocaine hcl for intravenous infusion, 10 mg |
1,005 |
742 |
$17K |
| 83021 |
|
368 |
223 |
$17K |
| 77001 |
|
201 |
160 |
$16K |
| 86800 |
|
801 |
688 |
$16K |
| J1453 |
Injection, fosaprepitant, 1 mg |
379 |
188 |
$16K |
| J1200 |
Injection, diphenhydramine hcl, up to 50 mg |
2,770 |
1,455 |
$15K |
| 83970 |
|
548 |
333 |
$15K |
| J7999 |
Compounded drug, not otherwise classified |
749 |
542 |
$15K |
| 83521 |
|
3,741 |
1,526 |
$14K |
| 83010 |
|
902 |
444 |
$14K |
| 88374 |
|
109 |
62 |
$14K |
| J1650 |
Injection, enoxaparin sodium, 10 mg |
846 |
377 |
$14K |
| A9575 |
Injection, gadoterate meglumine, 0.1 ml |
3,651 |
3,036 |
$14K |
| 86360 |
|
353 |
250 |
$13K |
| A9503 |
Technetium tc-99m medronate, diagnostic, per study dose, up to 30 millicuries |
595 |
485 |
$13K |
| 88309 |
|
84 |
55 |
$13K |
| 77293 |
|
54 |
40 |
$13K |
| 71275 |
Computed tomographic angiography, chest, with contrast material |
42 |
36 |
$13K |
| J1885 |
Injection, ketorolac tromethamine, per 15 mg |
1,384 |
676 |
$13K |
| 82024 |
|
184 |
156 |
$13K |
| 82105 |
|
830 |
669 |
$13K |
| 77470 |
|
17 |
13 |
$13K |
| 86870 |
|
89 |
38 |
$12K |
| 86880 |
|
502 |
265 |
$12K |
| C1729 |
Catheter, drainage |
218 |
135 |
$12K |
| 83880 |
|
388 |
306 |
$12K |
| 88365 |
|
130 |
42 |
$11K |
| 87088 |
|
1,108 |
868 |
$11K |
| J0780 |
Injection, prochlorperazine, up to 10 mg |
574 |
374 |
$11K |
| 82607 |
|
1,069 |
901 |
$11K |
| 87077 |
|
1,073 |
413 |
$11K |
| 94640 |
Pressurized or nonpressurized inhalation treatment for acute airway obstruction |
107 |
64 |
$11K |
| 83036 |
Hemoglobin; glycosylated (A1C) |
1,118 |
958 |
$10K |
| 82570 |
|
1,404 |
1,042 |
$10K |
| 88311 |
|
513 |
361 |
$9K |
| J2710 |
Injection, neostigmine methylsulfate, up to 0.5 mg |
124 |
78 |
$9K |
| 88173 |
|
156 |
100 |
$9K |
| 85652 |
|
1,245 |
960 |
$9K |
| 86706 |
|
528 |
437 |
$9K |
| 86704 |
|
633 |
510 |
$9K |
| J1644 |
Injection, heparin sodium, per 1000 units |
875 |
532 |
$8K |
| 74160 |
|
33 |
29 |
$8K |
| G0008 |
Administration of influenza virus vaccine |
321 |
253 |
$8K |
| 00731 |
|
71 |
60 |
$8K |
| 80061 |
Lipid panel |
833 |
686 |
$8K |
| 97530 |
Therapeutic activities, direct patient contact, each 15 minutes |
101 |
52 |
$8K |
| 83002 |
|
220 |
176 |
$8K |
| 91322 |
|
93 |
75 |
$8K |
| 97760 |
|
156 |
138 |
$7K |
| 86803 |
|
658 |
531 |
$7K |
| 84305 |
|
119 |
97 |
$7K |
| 84484 |
|
701 |
473 |
$7K |
| J2371 |
Injection, phenylephrine hydrochloride, 20 micrograms |
757 |
505 |
$7K |
| 00940 |
|
20 |
12 |
$7K |
| 92567 |
|
188 |
123 |
$7K |
| 86140 |
|
1,042 |
777 |
$6K |
| J2920 |
Injection, methylprednisolone sodium succinate, up to 40 mg |
217 |
124 |
$6K |
| J0690 |
Injection, cefazolin sodium, 500 mg |
344 |
173 |
$6K |
| 84156 |
|
951 |
744 |
$6K |
| 88331 |
|
71 |
29 |
$6K |
| 87040 |
|
189 |
70 |
$6K |
| J7042 |
5% dextrose/normal saline (500 ml = 1 unit) |
172 |
107 |
$6K |
| 87070 |
|
287 |
198 |
$6K |
| J2405 |
Injection, ondansetron hydrochloride, per 1 mg |
4,899 |
2,654 |
$5K |
| 83605 |
|
330 |
214 |
$5K |
| 86038 |
|
248 |
188 |
$5K |
| 87340 |
|
560 |
458 |
$5K |
| 84481 |
|
430 |
321 |
$5K |
| 93702 |
|
49 |
45 |
$5K |
| 82746 |
|
572 |
488 |
$5K |
| 83690 |
|
669 |
444 |
$5K |
| 74230 |
|
44 |
38 |
$5K |
| J0461 |
Injection, atropine sulfate, 0.01 mg |
156 |
68 |
$5K |
| 92526 |
|
89 |
65 |
$5K |
| 97166 |
|
73 |
50 |
$4K |
| J2916 |
Injection, sodium ferric gluconate complex in sucrose injection, 12.5 mg |
19 |
12 |
$4K |
| 99195 |
|
50 |
38 |
$4K |
| 82550 |
|
516 |
365 |
$4K |
| 87389 |
Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies |
199 |
165 |
$4K |
| 92611 |
|
54 |
54 |
$4K |
| J2060 |
Injection, lorazepam, 2 mg |
459 |
224 |
$4K |
| 82043 |
|
394 |
344 |
$4K |
| 86316 |
|
163 |
142 |
$4K |
| 99203 |
Office or other outpatient visit for the evaluation and management of a new patient, low complexity |
57 |
51 |
$3K |
| 74220 |
|
37 |
28 |
$3K |
| 84702 |
|
227 |
186 |
$3K |
| J8540 |
Dexamethasone, oral, 0.25 mg |
5,100 |
2,405 |
$3K |
| 00300 |
|
15 |
12 |
$3K |
| 82232 |
|
69 |
53 |
$3K |
| 86300 |
|
61 |
49 |
$3K |
| 87536 |
|
33 |
25 |
$2K |
| 51798 |
|
70 |
55 |
$2K |
| 81002 |
|
258 |
117 |
$2K |
| J0665 |
Injection, bupivicaine, not otherwise specified, 0.5 mg |
306 |
221 |
$2K |
| 81003 |
|
319 |
253 |
$2K |
| 85018 |
|
539 |
389 |
$2K |
| J1171 |
Injection, hydromorphone, 0.1 mg |
209 |
99 |
$2K |
| 85384 |
|
117 |
63 |
$2K |
| 90686 |
|
121 |
86 |
$2K |
| 90480 |
|
86 |
70 |
$2K |
| 85240 |
|
36 |
25 |
$2K |
| 87205 |
|
247 |
178 |
$2K |
| 0004A |
|
54 |
54 |
$2K |
| 96368 |
|
89 |
53 |
$2K |
| 87186 |
|
217 |
140 |
$2K |
| J0295 |
Injection, ampicillin sodium/sulbactam sodium, per 1.5 gm |
121 |
73 |
$2K |
| 82330 |
|
69 |
49 |
$1K |
| J1630 |
Injection, haloperidol, up to 5 mg |
383 |
266 |
$1K |
| Q0162 |
Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen |
1,202 |
551 |
$1K |
| 73502 |
|
12 |
12 |
$1K |
| 74018 |
|
36 |
27 |
$1K |
| 85014 |
|
319 |
231 |
$1K |
| 90662 |
|
73 |
60 |
$1K |
| J0736 |
Injection, clindamycin phosphate, 300 mg |
23 |
15 |
$1K |
| J2003 |
Injection, lidocaine hydrochloride, 1 mg |
218 |
181 |
$1K |
| 86644 |
|
32 |
26 |
$997.92 |
| J1596 |
Injection, glycopyrrolate, 0.1 mg |
171 |
140 |
$923.62 |
| C1894 |
Introducer/sheath, other than guiding, other than intracardiac electrophysiological, non-laser |
20 |
20 |
$866.45 |
| J2370 |
Injection, phenylephrine hcl, up to 1 ml |
22 |
14 |
$824.16 |
| A9541 |
Technetium tc-99m sulfur colloid, diagnostic, per study dose, up to 20 millicuries |
17 |
13 |
$823.19 |
| J9181 |
Injection, etoposide, 10 mg |
35 |
12 |
$814.47 |
| 82150 |
|
153 |
90 |
$813.53 |
| 85397 |
|
14 |
12 |
$751.35 |
| J3420 |
Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg |
76 |
52 |
$735.81 |
| 97763 |
|
15 |
14 |
$717.91 |
| 84132 |
|
114 |
69 |
$685.14 |
| 86431 |
|
52 |
47 |
$594.71 |
| 85049 |
|
79 |
44 |
$575.34 |
| 86480 |
|
13 |
12 |
$573.42 |
| 87449 |
|
24 |
12 |
$536.63 |
| 0002A |
|
16 |
16 |
$501.18 |
| J3260 |
Injection, tobramycin sulfate, up to 80 mg |
28 |
12 |
$499.43 |
| G0009 |
Administration of pneumococcal vaccine |
15 |
12 |
$465.92 |
| 83935 |
|
31 |
24 |
$382.43 |
| J0688 |
Injection, cefazolin sodium (hikma), not therapeutically equivalent to j0690, 500 mg |
60 |
42 |
$336.46 |
| 90656 |
|
28 |
26 |
$287.70 |
| 82977 |
|
27 |
24 |
$280.51 |
| L8000 |
Breast prosthesis, mastectomy bra, without integrated breast prosthesis form, any size, any type |
55 |
29 |
$270.65 |
| J2004 |
Injection, lidocaine hcl with epinephrine, 1 mg |
45 |
41 |
$255.90 |
| 85613 |
|
16 |
13 |
$252.18 |
| 0753T |
|
745 |
687 |
$244.30 |
| 84480 |
|
15 |
13 |
$239.50 |
| J3480 |
Injection, potassium chloride, per 2 meq |
20 |
12 |
$239.10 |
| J1642 |
Injection, heparin sodium, (heparin lock flush), per 10 units |
774 |
411 |
$220.19 |
| 85670 |
|
16 |
13 |
$138.46 |
| 91300 |
|
107 |
106 |
$116.55 |
| J1920 |
Injection, labetalol hydrochloride, 5 mg |
142 |
95 |
$113.99 |
| 0754T |
|
285 |
269 |
$109.48 |
| Q0164 |
Prochlorperazine maleate, 5 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen |
269 |
155 |
$62.76 |
| J9370 |
Vincristine sulfate, 1 mg |
17 |
12 |
$28.11 |
| J7512 |
Prednisone, immediate release or delayed release, oral, 1 mg |
63 |
38 |
$6.91 |
| G1004 |
Clinical decision support mechanism national decision support company, as defined by the medicare appropriate use criteria program |
614 |
449 |
$0.03 |